Auron Therapeutics
Auron Therapeutics is a clinical-stage biotechnology company focused on developing life-saving therapies by targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory diseases. Utilizing their proprietary AI/ML-powered platform, AURIGIN™, they map cancer cell states to identify drivers of disease and develop targeted therapies. Their lead product, AUTX-703, is in Phase 1 clinical trials for advanced hematologic malignancies, addressing cancers with high mortality rates such as acute myeloid leukemia, small-cell lung cancer, and neuroendocrine prostate cancer. The company combines expertise in biology, medicinal chemistry, and computational science, working closely with leading physician-scientists to deliver effective and durable treatments. Auron Therapeutics aims to transform cancer treatment by focusing on cell state drug development to offer patients longer, higher quality lives.
Auron Therapeutics
Auron Therapeutics is a clinical-stage biotechnology company focused on developing life-saving therapies by targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory diseases. Utilizing their proprietary AI/ML-powered platform, AURIGIN™, they map cancer cell states to identify drivers of disease and develop targeted therapies. Their lead product, AUTX-703, is in Phase 1 clinical trials for advanced hematologic malignancies, addressing cancers with high mortality rates such as acute myeloid leukemia, small-cell lung cancer, and neuroendocrine prostate cancer. The company combines expertise in biology, medicinal chemistry, and computational science, working closely with leading physician-scientists to deliver effective and durable treatments. Auron Therapeutics aims to transform cancer treatment by focusing on cell state drug development to offer patients longer, higher quality lives.